Bioventus (BVS)
(Delayed Data from NSDQ)
$7.17 USD
+0.10 (1.41%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $7.16 -0.01 (-0.14%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth D Momentum C VGM
Balance Sheet
Fiscal Year End for Bioventus Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 37 | 32 | 49 | 87 | 0 |
Receivables | 123 | 137 | 125 | 88 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 91 | 85 | 62 | 29 | 0 |
Other Current Assets | 17 | 19 | 27 | 8 | 0 |
Total Current Assets | 268 | 273 | 263 | 212 | 0 |
Net Property & Equipment | 37 | 28 | 23 | 7 | 0 |
Investments & Advances | 3 | 3 | 29 | 19 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 490 | 1,052 | 843 | 241 | 0 |
Deposits & Other Assets | 0 | 0 | 50 | 0 | 0 |
Total Assets | 811 | 1,373 | 1,226 | 494 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 23 | 38 | 17 | 4 | 0 |
Current Portion Long-Term Debt | 28 | 33 | 18 | 15 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 120 | 112 | 142 | 99 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 121 | 4 | 4 | 0 |
Total Current Liabilities | 176 | 304 | 181 | 123 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 154 | 134 | 3 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 367 | 385 | 340 | 173 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 46 | 189 | 38 | 51 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 590 | 1,032 | 692 | 350 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 494 | 482 | 465 | 0 | 0 |
Retained Earnings | -322 | -165 | -7 | -145 | 0 |
Other Equity | 48 | 24 | 75 | 289 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 221 | 340 | 534 | 144 | 0 |
Total Liabilities & Shareholder's Equity | 811 | 1,373 | 1,226 | 494 | 0 |
Total Common Equity | 221 | 340 | 534 | 144 | 0 |
Shares Outstanding | 79.00 | 77.80 | 75.30 | NA | NA |
Book Value Per Share | 2.80 | 4.37 | 7.09 | 0.00 | 0.00 |
Fiscal Year End for Bioventus Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 25 | 37 | 27 | 29 |
Receivables | NA | 126 | 123 | 113 | 120 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 97 | 91 | 98 | 96 |
Other Current Assets | NA | 18 | 17 | 12 | 15 |
Total Current Assets | NA | 266 | 268 | 249 | 261 |
Net Property & Equipment | NA | 35 | 37 | 40 | 42 |
Investments & Advances | NA | 3 | 3 | 7 | 7 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 478 | 490 | 501 | 513 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 794 | 811 | 811 | 837 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 19 | 23 | 18 | 41 |
Current Portion Long-Term Debt | NA | 36 | 28 | 20 | 11 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 114 | 120 | 119 | 122 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 5 | 5 | 5 | 5 |
Total Current Liabilities | NA | 173 | 176 | 161 | 179 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 1 | 1 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 355 | 367 | 375 | 375 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 46 | 49 | 50 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 577 | 590 | 585 | 604 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 497 | 494 | 492 | 491 |
Retained Earnings | NA | -326 | -322 | -315 | -308 |
Other Equity | NA | 46 | 48 | 49 | 51 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 217 | 221 | 226 | 233 |
Total Liabilities & Shareholder's Equity | NA | 794 | 811 | 811 | 837 |
Total Common Equity | 0 | 217 | 221 | 226 | 233 |
Shares Outstanding | 79.10 | 79.10 | 79.00 | 78.70 | 78.50 |
Book Value Per Share | 0.00 | 2.75 | 2.80 | 2.88 | 2.97 |